Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine

Authors:

Vondeling G, Palaka E, Livings C, Naik J and Sullivan W

Publication type:

Conference Proceedings – Poster

Publication Name:

Virtual ISPOR Europe 2020

Citation:

Vondeling G, Palaka E, Livings C, Naik J and Sullivan W. Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine. Virtual ISPOR Europe 2020. 16-19 November 2020. Poster PCN141.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies